AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 699507 — intervention group
Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 10
Study 31903600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transversus abdominis plane (TAP) block
Number of subjects: 180
Study 31903600 — intervention group
Group type: COMPARATOR
Intervention: Combined general-thoracic epidural anaesthesia (TEA)
Number of subjects: 180
Study 31903600 — intervention group
Group type: COMPARATOR
Intervention: Standard general anaesthesia (GA)
Number of subjects: 180
Study 30642326 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise programme (2 weekly sessions for 6 months, including at least 30 min of moderate intensity activity)
Number of subjects: 312
Study 30642326 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant drug treatment (habitually used in clinical practice)
Number of subjects: 312
Study 27856208 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hMSCs
Number of subjects: 37
Study 27856208 — intervention group
Group type: COMPARATOR
Intervention: Autologous hMSCs
Number of subjects: 37
Study 25572025 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation everolimus-eluting stents (EES)
Number of subjects: 625
Study 25572025 — intervention group
Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 625
Study 25030489 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction cards
Number of subjects: 188
Study 25030489 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 188
Study 25030489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 23085365 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine in Trichuris trichiura negative subjects
Number of subjects: 20
Study 23085365 — intervention group
Group type: COMPARATOR
Intervention: GMZ2 vaccine in Trichuris trichiura positive subjects
Number of subjects: 20
Study 23085365 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory B-cell response in T. trichiura negative individuals
Number of subjects: 20
Study 23085365 — intervention group
Group type: COMPARATOR
Intervention: Memory B-cell response in T. trichiura positive individuals
Number of subjects: 20
Study 20518324 — intervention group
Group type: EXPERIMENTAL
Intervention: JEV-L
Number of subjects: 12
Study 20518324 — intervention group
Group type: EXPERIMENTAL
Intervention: JEV-I (Vero)
Number of subjects: 12
Study 20518324 — intervention group
Group type: EXPERIMENTAL
Intervention: JEV-I (PHK)
Number of subjects: 12
Study 20518324 — intervention group
Group type: COMPARATOR
Intervention: Comparison of JEV-I (Vero) vs JEV-I (PHK)
Number of subjects: 12
Study 17301848 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy
Number of subjects: 60
Study 15342892 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start Program (HSP)
Number of subjects: 643
Study 11232608 — intervention group
Group type: COMPARATOR
Intervention: VVI‐ICD
Number of subjects: 92
Study 11232608 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐ICD
Number of subjects: 92
Study 9844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome with comorbidity (N = 23)
Number of subjects: 46
Study 9844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome without comorbidity (N = 23)
Number of subjects: 46
Study 9844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome with severe symptoms (N = 23)
Number of subjects: 46
Study 9844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome with fewer and less severe symptoms (N = 23)
Number of subjects: 46
Study 9844981 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 22)
Number of subjects: 46
Study 7926296 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to microalbuminuria
Number of subjects: 65
Study 7926296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprogressors
Number of subjects: 65
Study 7926296 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 65
Study 2689255 — intervention group
Group type: EXPERIMENTAL
Intervention: trimoprostil 750 micrograms taken 4 times daily
Number of subjects: 44
Study 2689255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 6108128 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.25‐0.50 mg)
Number of subjects: 0
Study 6108128 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25‐0.50 mg)
Number of subjects: 0
Study 6108128 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.6 mg)
Number of subjects: 0
Study 29939239 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support programme
Number of subjects: 12
Study 29939239 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 12
Study 28741429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan delivered via Adhesive Dermally‐Applied Microarray (ADAM)
Number of subjects: 20
Study 28741429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan via ADAM
Number of subjects: 20
Study 26001033 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 722
Study 26001033 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 722
Study 23414763 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing Durable Barrier Cream (MDBC)
Number of subjects: 318
Study 23414763 — intervention group
Group type: COMPARATOR
Intervention: 10% Glycerine Cream (Sorbolene)
Number of subjects: 318
Study 21812264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hualiu recipe (HLR)
Number of subjects: 110
Study 21812264 — intervention group
Group type: COMPARATOR
Intervention: Guizhi Fuling Capsule
Number of subjects: 110
Study 19950299 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral MLN3897 once daily for 12 weeks while continuing to receive MTX once a week
Number of subjects: 0
Study 19950299 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo once daily for 12 weeks while continuing to receive MTX once a week
Number of subjects: 0
Study 18722214 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A), 25 units injected into each inferior turbinate (total 50 units)
Number of subjects: 39
Study 18722214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroid injection (triamcinolone), 1 cc (20 mg/mL) injected into each inferior turbinate
Number of subjects: 39
Study 18722214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline), 1 cc injected into each inferior turbinate
Number of subjects: 39
Study 15702061 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Group (L) 30 ml of 0.5% levobupivacaine
Number of subjects: 80
Study 15702061 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine Group (R) 0.75% ropivacaine
Number of subjects: 80
Study 15702061 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Group (L)
Number of subjects: 80
Study 15702061 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine Group (R)
Number of subjects: 80
Study 11800193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min competing response duration
Number of subjects: 0
Study 11800193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min competing response duration
Number of subjects: 0
Study 11800193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-s competing response duration
Number of subjects: 0
Study 9428251 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved management of STDs in intervention communities
Number of subjects: 12537
Study 9428251 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 12537
Study 9428251 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved management of STDs
Number of subjects: 12537
Study 8150762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g i.v. bd
Number of subjects: 55
Study 8150762 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g i.v. tds
Number of subjects: 55
Study 3776448 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 227
Study 3776448 — intervention group
Group type: COMPARATOR
Intervention: 70% isopropyl alcohol
Number of subjects: 227
Study 11795430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman-Birk Inhibitor Concentrate (BBIC)
Number of subjects: 0
Study 30623534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5%, 5 mL)
Number of subjects: 46
Study 30623534 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 mL)
Number of subjects: 46
Study 29321338 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training program for emergency unit staff (videos and interactive simulation workshops)
Number of subjects: 691
Study 29321338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 691
Study 28300812 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Number of subjects: 301
Study 28300812 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo naltrexone + guanfacine (NP+G)
Number of subjects: 301
Study 28300812 — intervention group
Group type: COMPARATOR
Intervention: naltrexone + placebo guanfacine (N+GP)
Number of subjects: 301
Study 28300812 — intervention group
Group type: COMPARATOR
Intervention: double placebo (NP+GP)
Number of subjects: 301
Study 24231625 — intervention group
Group type: EXPERIMENTAL
Intervention: AESIT at 50% of vLTP1 (18.6 ± 0.7 km/h)
Number of subjects: 8
Study 24231625 — intervention group
Group type: EXPERIMENTAL
Intervention: AESIT at 55% of vLTP1 (20.2 ± 0.6 km/h)
Number of subjects: 8
Study 24231625 — intervention group
Group type: EXPERIMENTAL
Intervention: AESIT at 60% of vLTP1 (22.3 ± 0.7 km/h)
Number of subjects: 8
Study 24231625 — intervention group
Group type: COMPARATOR
Intervention: Comparison of La at 50% of vLTP1 and La at vLTP1
Number of subjects: 8
Study 22267280 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (PIO) 30 mg once daily
Number of subjects: 71
Study 22267280 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (MET) 1000 mg twice daily
Number of subjects: 71
Study 22267280 — intervention group
Group type: COMPARATOR
Intervention: healthy male controls
Number of subjects: 71
Study 22267280 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 71
Study 22267280 — intervention group
Group type: EXPERIMENTAL
Intervention: PIO-treated patients
Number of subjects: 71
Study 22267280 — intervention group
Group type: EXPERIMENTAL
Intervention: MET-treated patients
Number of subjects: 71
Study 20337077 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit endodontic treatment
Number of subjects: 138
Study 20337077 — intervention group
Group type: COMPARATOR
Intervention: Two-visit endodontic treatment (calcium hydroxide as interappointment medicament)
Number of subjects: 138
Study 20337077 — intervention group
Group type: COMPARATOR
Intervention: Two-visit endodontic treatment
Number of subjects: 138
Study 17377528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 then 6 g/day
Number of subjects: 0
Study 17377528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 then 8 g/day
Number of subjects: 0
Study 17377528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15599127 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure with behavioral experiments
Number of subjects: 6
Study 15599127 — intervention group
Group type: COMPARATOR
Intervention: Operant graded activity program
Number of subjects: 6
Study 11879108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 gel (100 mg) and condoms
Number of subjects: 1251
Study 11879108 — intervention group
Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1251
Study 10434239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg twice daily)
Number of subjects: 26
Study 10434239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8574711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily plus Cisapride 20 mg twice daily
Number of subjects: 344
Study 8574711 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily alone
Number of subjects: 344
Study 2186273 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (100 U/kg thrice weekly by intravenous bolus)
Number of subjects: 63
Study 2186273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2186273 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 63
Study 526848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast interferon (300 u)
Number of subjects: 11
Study 526848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter sleep duration
Number of subjects: 160
Study 30121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep variables
Number of subjects: 160
Study 28231304 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast high in saturated fat and added sugar (Experimental condition)
Number of subjects: 0
Study 28231304 — intervention group
Group type: COMPARATOR
Intervention: Healthier breakfast (Control condition)
Number of subjects: 0
Study 25902327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oxytocin infusion at 44.2 IU/h (ED90) in laboring women
Number of subjects: 70
Study 25902327 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic oxytocin infusion at 16.2 IU/h (ED90) in nonlaboring women
Number of subjects: 70
Study 25902327 — intervention group
Group type: EXPERIMENTAL
Intervention: Requirement for additional uterotonic agents in laboring women
Number of subjects: 70
Study 25902327 — intervention group
Group type: COMPARATOR
Intervention: Requirement for additional uterotonic agents in nonlaboring women
Number of subjects: 70
Study 25902327 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of side effects in laboring women
Number of subjects: 70
Study 25902327 — intervention group
Group type: COMPARATOR
Intervention: Incidence of side effects in nonlaboring women
Number of subjects: 70
Study 23222879 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-servoventilation (ASV) with optimal medical management, n=37
Number of subjects: 72
Study 23222879 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management alone, n=35
Number of subjects: 72
Study 23222879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 21340022 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low caloric diet-induced weight loss
Number of subjects: 96
Study 21340022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein level
Number of subjects: 96
Study 21340022 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index (GI) level
Number of subjects: 96
Study 21340022 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictor panel of 15 variables
Number of subjects: 96
Study 21340022 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with 9 blood analytes
Number of subjects: 96
Study 19551860 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT polymorphism (rs4818)
Number of subjects: 4470
Study 17580734 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol, 20 mg once daily
Number of subjects: 112
Study 17580734 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate, 50 mg twice daily
Number of subjects: 112
Study 17580734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 112
Study 15090020 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% cream applied BID
Number of subjects: 15
Study 15090020 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 15
Study 11764014 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study 11764014 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of alcohol consumption
Number of subjects: 0
Study 11764014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol)
Number of subjects: 0
Study 9236451 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 70
Study 9236451 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 70
Study 8431341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 5 mg in saline 25 ml
Number of subjects: 20
Study 8431341 — intervention group
Group type: COMPARATOR
Intervention: Saline 25 ml intra-articularly (Control)
Number of subjects: 20
Study 3315587 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30U in 5 minutes
Number of subjects: 25
Study 3315587 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase 1,500,000U over 60 minutes
Number of subjects: 25
Study 3315587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both APSAC and streptokinase
Number of subjects: 25
Study 3315587 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 25
Study 31961675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian process models with composite kernels trained on 500 randomly selected ab initio points
Number of subjects: 500
Study 31961675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian process models with composite kernels trained on 1500 potential energy points
Number of subjects: 500
Study 31464938 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking (APS) combined with tranexamic acid, n = 43
Number of subjects: 86
Study 31464938 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid alone (Control group), n = 43
Number of subjects: 86
Study 29166890 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) in combination with early motion Physical Therapy (PT) supervised by a physical therapist
Number of subjects: 0
Study 29166890 — intervention group
Group type: COMPARATOR
Intervention: Early motion Physical Therapy (PT) supervised by a physical therapist
Number of subjects: 0
Study 29166890 — intervention group
Group type: COMPARATOR
Intervention: Outpatient supervised Physical Therapy (PT) from postoperative day seven till ten
Number of subjects: 0
Study 26405670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid irrigation
Number of subjects: 100
Study 26405670 — intervention group
Group type: COMPARATOR
Intervention: Topical and systemic antibiotics
Number of subjects: 100
Study 23955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 202
Study 23955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 202
Study 23955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both counseling and nicotine patch
Number of subjects: 202
Study 23955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent to both
Number of subjects: 202
Study 21484904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic cervical length
Number of subjects: 154
Study 21484904 — intervention group
Group type: COMPARATOR
Intervention: Bishop score
Number of subjects: 154
Study 18280205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (1000mg)
Number of subjects: 18
Study 18280205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17009270 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (15 mg/kg of ideal body weight/day)
Number of subjects: 27
Study 17009270 — intervention group
Group type: COMPARATOR
Intervention: IV saline (control)
Number of subjects: 27
Study 14717341 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 3200
Study 14717341 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 3200
Study 10561111 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 22
Study 10561111 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 22
Study 8885944 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl Blue (HAB)
Number of subjects: 61
Study 8885944 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study 1950033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 12
Study 1950033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg
Number of subjects: 12
Study 1950033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg
Number of subjects: 12
Study 1950033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (all doses)
Number of subjects: 12
Study 6404914 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8
Study 6404914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31504554 — intervention group
Group type: COMPARATOR
Intervention: GHB (50 mg/kg body weight)
Number of subjects: 20
Study 31504554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28335841 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV plus optimized medical therapy (OMT)
Number of subjects: 126
Study 28335841 — intervention group
Group type: COMPARATOR
Intervention: OMT alone (control)
Number of subjects: 126
Study 25559612 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood systolic blood pressure (BP)
Number of subjects: 657
Study 25559612 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in systolic BP from childhood to adulthood
Number of subjects: 657
Study 25559612 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood systolic BP
Number of subjects: 657
Study 23444286 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine/pyridoxine delayed-release combination (Diclectin)
Number of subjects: 68
Study 21148606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine via perineural catheter (Group A)
Number of subjects: 66
Study 21148606 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline via perineural catheter (Group B)
Number of subjects: 66
Study 21148606 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol (Group C)
Number of subjects: 66
Study 19293292 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education programme
Number of subjects: 44